Global Etoricoxib Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Etoricoxib Market Research Report 2024
Etoricoxib is a selective COX-2 inhibitor used to relieve dental pain after moderate surgery as a short-term treatment and inflammation and pain symptoms of various forms of arthritis.
According to Mr Accuracy reports’s new survey, global Etoricoxib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Etoricoxib market research.
Key manufacturers engaged in the Etoricoxib industry include Morepen Laboratories, Merck & Co, Frosst Iberica SA, Metrochem API, Atom Pharma, Hema Pharmaceuticals, Beijing Tide Pharmaceutical, Qilu Pharmaceutical and Shanghai Shyndec Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Etoricoxib were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Etoricoxib market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Etoricoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Morepen Laboratories
Merck & Co
Frosst Iberica SA
Metrochem API
Atom Pharma
Hema Pharmaceuticals
Beijing Tide Pharmaceutical
Qilu Pharmaceutical
Shanghai Shyndec Pharmaceutical
Easton Biopharmaceuticals
Segment by Type
30 mg
60 mg
90 mg
120 mg
Hospital
Pharmacy
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Etoricoxib report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Etoricoxib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Etoricoxib market research.
Key manufacturers engaged in the Etoricoxib industry include Morepen Laboratories, Merck & Co, Frosst Iberica SA, Metrochem API, Atom Pharma, Hema Pharmaceuticals, Beijing Tide Pharmaceutical, Qilu Pharmaceutical and Shanghai Shyndec Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Etoricoxib were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Etoricoxib market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Etoricoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Morepen Laboratories
Merck & Co
Frosst Iberica SA
Metrochem API
Atom Pharma
Hema Pharmaceuticals
Beijing Tide Pharmaceutical
Qilu Pharmaceutical
Shanghai Shyndec Pharmaceutical
Easton Biopharmaceuticals
Segment by Type
30 mg
60 mg
90 mg
120 mg
Segment by Application
Hospital
Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Etoricoxib report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
